valu usd unless otherwis note
pipelin conserv guidanc valuat
view price-to-earnings ntm basi share trade discount
 level last seen year ago valuat reflect lack
confid guidanc award littl recognit promis
new product approv attract late-stag pipelin upcom
catalyst includ result april esketamin data
share favor outsid recess share
endur worst start year centuri februari
total return share includ dividend neg
compar price-to-earnings ntm consensu
estim share trade discount averag
 averag large-cap medic supplies/devic
peer coverag
guidanc organ revenu growth compar last
year adjust account differ prior
period adjust segment
ww organ revenu growth fall within
guidanc organ revenu growth signal
materi chang outlook year mid single-digit organ
growth pharma low single-digit growth devices/consum
segment would suffici achiev guidanc
mega-blockbust remain
brand stelara imbruvica darzalex xarelto invega
sustenna/trinza ww sale five jump y/i
exclud currenc estim ww sale mega-
blockbust increas brand account
pharmaceut segment sale estim y/i cc
make solid progress refresh pharma portfolio
two latest nme approv past month tremfya psoriasi
erleada pre-metastat prostat cancer contribut
ww revenu estim climb
contribut exce next year esketamin expect file
receiv fda review new indic sever
top-sel brand also advanc toward commerci
upcom catalyst reinforc pharma strength give clariti
devices/consum outlook event result
investor day efficaci safeti data
esketamin pivot trial result
demonstr jnj abil achiev mid single-digit organ growth
pharmaceut segment face remicad sale eros
investor day like lay strategi acceler growth
devic consum esketamin clinic data serv key input
frame sale expect launch trajectori
price prior trade day market close estimate unless otherwis note
forecast organ revenu growth
oper growth bp higher organ revenu
growth compar last year account
prior period adjust despit greater remicad sale
eros tougher year-over-year comp
expect organ growth mid single-digit rang
pharmaceut segment princip driver jnj revenu
earn growth valuat share
mega-blockbust
contribut new product main growth
driver segment mega-blockbust
brand ww annual peak sale potenti billion
stelara imbruvica darzalex xarelto invega
sustenna/trinza ww sale five brand
estim
ww sale mega-blockbust increas led
stelara imbruvica darzalex new brand tremfya
erleada contribut million sale
pharmaceut pipelin enough late-stag compound
produc steadi flow new drug nme
esketamin erdafitinib expect submit
approv year could market
manag share target nme file
least billion peak annual sale
esketamin studi treatment-
resist depress major depress disord
patient risk suicid ideat erdafitinib expand
jnj oncolog portfolio solid tumor
franchis good start manag laid
four-prong growth strategi two key brand
opsumit uptravi frequent earlier use
combin regimen pah treatment improv patient
respons extend treatment durat expand usag
new patient segment broaden geograph reach
brand
bloomberg capit market estim upside/downside/target
arriv price target use sum-of-the-
part sotp price-to-earnings analysi valu three segment
medic devic consum separ
base peer group multipl base case estim
assum mid-single-digit oper growth includ
low-single-digit organ growth exclud
margin expans share buyback price
target impli price-to-earnings multipl ep estim
 lift revenu growth basi point
restructur portfolio ration lead superior
leverag rel base case scenario
pharmaceut price rhetor lead legisl
chang govern negoti price
multipl ep estim y/i
assumpt
aggress eros remicad brand
biosimilar gener competit lack depress
revenu growth neg leverag dent
multipl downsid scenario impli
price-to-earnings multipl y/i ep estim
assumpt
pipelin conserv guidanc valuat creat attract risk/reward
share fallen favor past six week
potenti multi-billion dollar cancer treatment win approv two month ahead
schedul event bare get recognit stock market someth gone
amiss exactli occur recent case februari releas
data pivot trial apalutamid christen erleada show significantli
prolong metastasis-fre surviv castration-resist prostat cancer patient high risk
diseas progress less week later februari fda approv erleada
note press releas import drug patient lack adequ
altern larg unmet need pdufa date earli april began erleada
shipment februari
outsid recess share endur worst start year centuri
februari total return share includ dividend neg
compar thrice past year perform
wors first week year three case
economi recess financi market declin fell
januari februari
price-to-earnings ntm share trade discount averag
averag large-cap medic devic peer share continu
enjoy premium albeit smaller drg index pharmaceut compani
exhibit total return share past year
return februari year medic suppli devic
sentiment sour quickli
actual start posit note share hit all-tim intra-day high
januari nine day major stock market indic regist new
record sinc share fallen eras billion market
capit six week elev market volatil rise short-term long-term
interest rate debat drug price partli blame howev compani
specif factor deduc meet investor past month also appear
play
guidanc organ revenu growth step
perform pharmaceut busi strong gener believ
medic devic consum segment continu lag could
guidanc risk segment under-perform expect
prepar off-set remicad sale eros due biosimilar competit
gener risk zytiga risk appropri factor guidanc
limit upsid guidanc
one interpret manag comment may becom
necessari matur brand besid remicad zytiga encount gener
competit beyond
given factor price-to-earnings multipl expans limit could share becom valu
respons concerns/quest go follow
organ revenu growth compar last year account prior
period adjust despit greater remicad sale eros tougher year-over-
year comp expect organ growth also exclud fx mid single-
digit rang segment princip driver jnj revenu
earn growth valuat share
forti percent medic devic ww revenu actual grow mid single-
digit compar growth rate diversifi large-cap med-tech
compani howev weak spine product franchis weigh
overal growth combin new product divestitur non-cor asset
improv overal growth profil consum market condit unlik
chang much last year easier comp continu solid perform beauti
over-the-counter help deliv slightli higher revenu growth howev
growth mega-blockbust stelara imbruvica darzalex xarelto invega
sustenna/trinza contribut new product tremfya erleada full
year sale pah franchis last year actelion acquisit opsumit
uptravi suffici view off-set remicad sale declin
overcom gener competit zyitga becom realiti
manag histori exercis good financi disciplin sinc fund
never issu healthi aaa debt rate crucial factor
assess manag approach toward unlik chang new
 tax regim howev believ manag preemptiv address sale
eros organ growth alon insuffici
jnj current valuat give much credit variou risk factor mention
littl credit abund growth opportun opinion
past year buy share trade discount
led excess total return subsequ month
believ share turn valu trap
guidanc organ revenu growth compar last
year adjust
let start place guidanc context perform topic
crop call investor sinc compani result issu januari
initi guidanc organ revenu growth differ
guidanc guidanc exclud currenc net effect
acquisit divestitur complet year organ growth turn
miss low end initi guidanc basi point pharmaceut sale grew
ww revenu growth sluggish basi point year-over-year rebound
strongli increas
howev segment revenu growth rate reduc due
favor prior period adjust ppa record bigger
similar adjust adjust reserv set asid
discount rebat payer manag medicaid remicad procrit stelara
simponi xarelto brand affect higher ppa
account ppa segment growth goe basi
point basi point adjust ww organ revenu
growth turn instead respect
full year growth rate becom segment
compani adjust higher ppa ww revenu growth
within origin guidanc thu guidanc rang ww revenu
bracket adjust growth rate signal
materi chang busi outlook
exhibit year-over-year revenu growth exclud net impact acquisit
divestitur growth rate highlight grey tabl bottom exclud prior
period adjust segment
reportedrevenu growth total adjust highlight revenu growth total medic suppli devic
opportun risk factor revenu guidanc
jnj organ revenu growth guidanc yield rang billion
billion base calcul abbott medic optic februari actelion
june exclud calcul includ off-set asset sale
complet codman neurosurgeri octob add basi point
revenu growth give rang billion billion oper revenu
final currenc expect tailwind basi point take report
revenu growth report revenu rang billion
billion revenu guidanc provid jnj earn press releas
provid revenu guidanc individu segment therefor made
assumpt segment estim organ revenu growth
comparison discuss previou section
prior period adjust taken consider estim organ revenu growth
medic devic rang includ
divestitur codman consum segment forecast organ revenu growth
neg thu analysi slightli faster growth
medic devic consum abl off-set slightli slower growth
exhibit interpret jnj revenu guidanc
stage instruct examin growth driver headwind segment
like confront year analysi offer clue upsid risk manag
guidanc start segment three main growth driver
segment
imbruvica darzalex xarelto
sustenna/trinza ww sale five brand jump year-over-year
exclud currenc growth estim
ww sale mega-blockbust increas led stelara imbruvica
darzalex mega-blockbust account segment
sale estim billion
new brand tremfya erleada tremfya psoriasi receiv eu
approv juli novemb respect tremfya exit
approxim million annual run-rat ww sale estim million
climb million erleada receiv fda approv within month
revenuesy/i growthin millionlowhighlowhighww revenu acquisitions/divestitur organ growth organ net excl fx incl fx medic suppli devic
regulatori file initi indic pre-metastat prostat cancer diseas
demonstr signific success zytiga ww sale billion
erleada pend eu approv base expedit review drug receiv
 approv rule erleada sale estim
million refer zytiga first approv april europ
septemb gener ww sale million
pah franchis opsumit uptravi brand came acquisit
actelion sinc transact close june segment sale
includ six month contribut actelion ww sale estim
two brand billion increment revenu contribut million
previou public commun manag laid four-prong strategi
acceler growth pah franchis play next year
move headwind segment promin
continu sale eros remicad biosimilar competit
intern ww remicad sale billion decreas
prescript remicad report iqvia flat versu therefor
sale declin price-rel ww remicad sale estim billion
also face rapid sale eros invokana/invokamet follow chang label
last year ww sale drop account franchis sale
prescript show sign stabil fall first week
correspond period last year model declin sale partial off-set
modest growth intern
final procrit tracleer face gener competit year procrit sale
alreadi declin last year y/i assum declin sale year
tracleer sale estim million one-third
exhibit growth driver headwind jnj three segment revenu growth rate shown tabl
oper growth rate includ net impact acquisit divestitur
pharmaceuticalmed devicesww revenu million oper growthww revenu million oper driversheadwindsgrowth driversheadwindsmega-blockbust biosimilar/gener vision cardiovascularspine/oth diabet stelara imbruvica darzalexremicad procritadvanc surgeryspecialti surgeryxarelto invega sustenna/trinzatracleerconsumernew brand brand steep declin ww revenu million oper growthtremfya brand older edurantrisperd franchis growth driversheadwindsopsumit uptravibeauti otcremain product categori medic suppli devic
medic devic mix fast-grow franchis off-set busi matur market
face signific competit cardiovascular vision advanced/gener surgeri
belong first categori spine singl largest franchis pressur vision
bolster februari acquisit abbott medic optic grow
mid high single-digit vision account medic devic sale
advanc surgeri ww revenu increas sever product categori within
advanc surgeri medic devic revenu perform well includ
endocutt biosurgeri within cardiovascular electrophysiolog grown
double-digit past two year result jnj competitor also shown
strong growth electrophysiolog among fastest grow end-market medic
devic right cardiovascular account ww medic devic revenu thu
medic devic ww revenu origin vision advanc surgeri
cardiovascular sustain mid single-digit growth better
spine busi biggest headwind medic devic ww
spine sale fell respect sale declin faster
sale spine big franchis account medic devic
sale sever factor contribut perform includ end market soft
 product launch delay sever new product launch plan
help improv growth specialti surgeri medic devic
revenu well either revenu lower year-over-year host
biennial medic devic consum segment focus investor day may
expect hear compani growth strategi includ new product
consum segment solid organ growth endur difficult
neg organ growth howev better
encourag lead indic easier comp also help growth beauti
over-the-counter product franchis best within consum account
segment revenu estim combin sale two franchis grow
howev softer sale babi oral like push
consum segment sale closer growth year plan relaunch sever
babi brand year detail could share may investor day
anoth acquisit scale vogu intern purchas price billion
appear unlik near-term invest region brand later
introduc global compani note success approach russia china
anoth topic interest investor day
put piec togeth revenu model
ww revenu estim billion y/i exclud currenc
estim upper half guidanc billion billion key assumpt
underli estim follow
pharmaceut ww revenu estim billion y/i exclud fx
sale growth mega-blockbust vs
million combin sale tremfya erleada
sale declin remicad
medic devic ww revenu estim billion y/i exclud fx
pro-forma sale growth vision assum abbott medic optic
transact close instead
mid single-digit growth advanc gener surgeri off-set low single-digit
declin specialti surgeri
declin orthoped sale mainli mid single-digit decreas
spine off-set low single-digit growth hip knee trauma
consum ww revenu estim billion y/i exclud fx
single-digit growth beauti over-the-counter categori
sale growth rest portfolio flat slightli posit
exhibit ww revenu estim fall upper half jnj guidanc
compani document capit market estim sale figur million
like sourc upsid revenu estim
mega-blockbust percentag point sale growth correspond million
ww sale prescript trend brand first six week year
carri momentum
revenu contribut erleada estim ww sale million
less half zytiga first year market back strength
clinic data lack adequ treatment pre-metastat cancer lead us
conclud sale estim could prove conserv howev would like
get sens drug uptak next month assess sale project
medic devic everi basi point revenu growth correspond million
ww revenu portfolio gener addit million ww sale
would push medic devic revenu growth exclud fx manag
highlight new product launch across portfolio mostli launch
schedul therefor scope upsid ww revenu estim
main risk factor level price eros remicad sale estim
billion reflect declin year-over-year sale remicad affect prior
period adjust discuss earlier report take account ppa
 sale estim lower last year assum mid-teen price declin
 remicad sale estim wait result get better
understand underli price trend gener competit zytiga also risk
factor sale estim billion assum earli introduct
gener present model declin zytiga sale get
clariti on-going patent litig reassess estim
geographi wwww revenu brand growth ww excl revenu medic suppli devic
pharmaceut pipelin enough late-stag compound
produc steadi flow new drug expand indic
alreadi secur approv one new molecular entiti earli apalutamid
erleada submit applic eu approv combin regimen
consist erleada zyitga plan file eu year
nme esketamin erdafitinib expect submit approv year
could market manag share target nme file
least billion peak annual sale
exhibit nme new indications/formul alreadi file regulatori approv phase clinic trial
esketamin studi treatment-resist depress major depress
disord patient risk suicid ideat among key attribut esketamin
non-invas intranas formul facilit rapid absorpt fast onset
action manag side-effect gener resolv within hour dose
drug administ observ healthcar provid improv
complianc challeng treat depress phase safeti efficaci trial
esketamin combin oral-antidepress cymbalta lexapro zoloft
effexor xr complet data submit present medic
confer data long-term safeti studi present next month
confer uk esketamin breakthrough therapi design gener
commit fda render decis within month applic file expect
file potenti approv earli
 molecular entiti nme new molecular entiti nme esketamineimetelstatponesimodtreatment-resist depress us/eu myelofibrosi us/eu relaps multipl sclerosi us/eu erdafitinibnirapariblumicitabinesolid tumor us/eu metastat castration-resist prostat cancer us/eu rsv infect us/eu apalutamid erleada seltorexantpimodivirpre-metastat prostat cancer eu adjunct treatment depress us/eu influenza us/eu new indic formulationsnew indic formulationsapalutamid zytigaimbruvicastelarachemo-nav prostat cancer us/eu frontlin mantl cell lymphoma us/eu ulcer coliti pediatr psoriasi us eu imbruvica combin rituxan treanda/bendeka simponi ariadiffus larg cell lymphoma us/eu relapsed/refractori indol non-hodgkin lymphoma us/eu juvenil idiopath arthriti us frontlin chronic lymphocyt leukemia us/eu combin rituxan/r-chop treanda/bendeka tremfyafrontlin waldenstrom macroglobulinemia us/eu frontlin chronic lymphocyt leukemia us/eu psoriat arthriti us/eu combin rituxan combin gazyva xareltoxareltofrontlin chronic graft-versus-host-diseas us/eu reduc mace risk chf patient signific cad us reduc mace risk cad pad patient us darzalexinfrainguin revascular us invokanafrontlin multipl myeloma transplant elig us/eu pediatr venou thromboembol us reduc fatal risk type diabet cvd risk us/eu combin velcad thalidomid dexamethason invokanaopsumitfrontlin multipl myeloma transplant inelig us/eu diabet nephropathi us/eu chronic thromboembol pulmonari hypertens us/eu combin velcad melphalan prednison rilpivirin edur long-act nanosuspens inject combin revlimid dexamethason hiv us/eu note snda xarelto file decemb multipl myeloma line us/eu paliperidon palmit month long-act injectablesnda invokana file us eu combin pomalyst dexamethason mainten treatment schizophrenia us/eu smolder multipl myeloma us/eu opsumitamyloidosi us/eu pediatr pulmonari hypertens us/eu subcutan formul us/eu uptravi intraven formulationerleadapulmonari hypertens us/eu metastat hormon sensit prostat cancer us/eu local prostat cancer us/eu medic suppli devic
erdafitinib expand jnj oncolog portfolio solid tumor approv first indic
erdafitinib pan-fibroblast growth factor receptor fgfr tyrosin kinas inhibitor
urotheli cancer clinicaltri gov show list patient phase trial
erdafitinib versu standard care consist chemotherapi mrk keytruda
patient advanc urotheli cancer select fgfr aberr progress
one prior line system therapi develop companion diagnost tool
use conjunct drug clinic studi underway lung cancer liver cancer
breast cancer esophag cancer
besid two nme file plan year expand label imbruvica
invokana opsumit respect imbruvica new indic includ frontlin
treatment chronic lymphocyt leukemia combin rituxan diffus larg
decemb submit supplement nda xarelto base posit result
compass trial releas last august compass random total patient
stabl coronari arteri diseas cad peripher arteri diseas pad three arm
xarelto mg twice daili plu aspirin mg daili xarelto alon mg twice daili
aspirin alon mg daili xarelto/aspirin combin found superior aspirin alon
efficaci statist signific differ observ xarelto alon
aspirin alon arm either primari secondari efficaci outcom combin
arm major bleed event manag believ compass potenti expand
target patient popul xarelto around million today figur two
three time higher depend final label
invokana label expans applic eu follow public canva
studi last year canva program integr data two trial involv total
particip type diabet high cardiovascular risk primari outcom
composit death cardiovascular caus non-fatal myocardi infarct non-fatal
stroke trial show patient treat invokana lower risk cardiovascular
event receiv placebo greater risk amput fda-
approv label invokana label revis juli add black-box warn
reflect higher risk lower-limb amput therefor new cardiovascular benefit
approv unlik return brand growth opinion
ww revenu estim billion includ million
esketamin sale contribut erdafitinib mid-teen growth xarelto compar
estim moder imbruvica growth low-
rang next year depend strength phase esketamin data
detail commerci plan drug emerg better posit assess
growth trajectori esketamin await erdafitinib data file timelin
add drug model
jnj busi plan four-year period includ line
extens addit nme line extens peak sale potenti million
new indic formul imbruvica darzalex erleada xarelto stelara
tremfya paliperidon palmit opsumit uptravi expect file
 rule catalyst year
gener cumul free cash flow billion repres
compound-annual-growth-rate hierarchi deploy intern invest fund
dividend rank ahead dividend payment rose compound-annual-growth-rate
total spend past four year exceed dividend billion
versu billion spend dedic singl transact actelion
transact announc januari close june
acquisit vogu intern close juli billion abbott medic optic
close februari account spend thu apart
transact spent billion four-year period primarili tuck-in
acquisit may simpli coincid worth note jnj three largest
deal past five year occur around time compani confront biosimilar
threat brand remicad
exhibit gener deploy
compani document capit market figur million
manag constantli emphas disciplin approach may explain
multi-billion transact recent year valuat
becom progress richer access oversea cash follow chang tax law
alter strict financi criteria potenti target must meet accord manag
end cash equival billion billion oversea
manag said earn call oversea cash readili repatri
 country-by-countri restrict howev around billion come
back immedi fund oper retir debt matur mention
possibl use repatri cash
howev financ realli constraint even larg transact
concern estim billion assum increas quarterli
dividend effect next payment still leav billion includ cash balanc
sheet share repurchas aaa-rat debt capac issu either
therefor time futur transact difficult predict believ
manag abil preemptiv address sale eros one-tim
natur big organ growth alon suffic earlier
expect gener competit zyitga type event mind
buy share trade discount
prove profit invest past year
share reach all-tim high last month trade price-to-earnings ntm
base consensu ep estim multipl discount
price-to-earnings ntm discount past year share
trade averag premium
reportedcf dividend total cash medic suppli devic
last time valuat discount big year ago follow
result guidanc follow month share
outperform sever percentag point smaller rectangl exhibit
share gener total return versu similarli
share trade discount sever month subsequ
good run follow month
contrast share trade premium gener
under-perform follow month exampl
thu contrarian invest style appear work well past year
surpris sinc clearli momentum stock howev believ analysi
suggest share turn valu trap underli fundament
typic bad precipit declin share may seem indic
exhibit orang line chart show premium discount jnj price-to-earnings ntm price-to-earnings ntm blue line chart
show excess total return share index follow month
valuat premium/discount vs excess return follow monthspremium returnperiodsin trade discountto gener follow positiveexcess return follow month medic suppli devic
guidanc estim
jnj guidanc follow
oper revenu growth exclud fx
gener competit remicad procrit tracleer
howev competit zytiga risperd consta prezista
pre-tax margin basi point y/i
tax rate
report ep includ favor fx
net interest expens million million
incom gain billion billion
revenu guidanc estim discuss length earlier report
rais ep estim due higher revenu estim
gone million billion currenc increas
revenu ep estim billion billion primarili
higher pharmaceut segment sale consensu estim revenu
ep billion estim ww
revenu billion exclud fx ep t/t consensu estim
billion
exhibit estim chang
exhibit sum-of-the-part valuat deriv price target
estimatesrevenu ww estimate ep contributioncontribut price targetconsum medic suppli devic
exhibit depict price chang share first week year go back
final exhibit report show excess total return share
index last year share outperform
done past year furthermor three year
share wors start year end
better year cours past perform
guarante futur return howev believ exhibit support view
share good long-term invest pullback like one see
like worth take advantag
exhibit total return share less total return excess return
return share medic suppli devic
price target base sum-of-the-part sotp analysi target price-to-earnings
multipl base year medic devic consum segment
respect correspond peer group multipl
assign premium multipl segment
superior growth outlook compar peer pharmaceut segment contribut toward
price target medic devic consum price target impli blend
price-to-earnings multipl ep estim y/i basi
outperform rate share
risk rate price target
face risk typic global diversifi healthcar compani includ
slump navig fda may impedi price target rate
johnson johnson one largest diversifi healthcar busi
world oper compani encompass broad rang product across
healthcar field compani world-wide busi divid three main segment
medic devic diagnost sale consum
